Experimental pill for lung cancer with EGFR or HER2 changes
Part of Cancer, Lungs & breathing clinical trials.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lung cancer must be advanced (spread to nearby tissues or other parts of the body) and have a change (mutation) in the EGFR or HER2 gene.
- You need to have at least one tumor outside the brain that can be measured on a scan.
- You should be able to take care of yourself (able to do daily activities without major help).
- You must be expected to live at least 3 more months.
- Your health must be generally good, with adequate blood counts and kidney/liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (GFH375) alone or with another drug for people with a specific gene change (KRAS G12D) in advanced lung cancer. It aims to shrink or slow the cancer, possibly better than current standard treatments.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
This study tests an oral pill (BPI-361175) for people with advanced non-small cell lung cancer that has specific EGFR mutations, especially when standard EGFR-targeted treatments are no longer working. The goal is to see if it can shrink tumors or slow growth.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.